Compass Shows PFS Benefit For Tovecimig With Confounding OS Result
A trial testing the DLL4/VEGF-A bispecific antibody tovecimig in individuals with biliary tract cancer was confounded by a high-rate of crossover treatment, Compass said.
Scrip - April 27, 2026

Months After Stryker Cybersecurity Attack, Medtronic Hit As Healthcare Threats Reach Record High
Stryker's March cyberattack will cost it a material Q1 hit. Now Medtronic has disclosed unauthorized access to its corporate IT systems. Two of medtech's biggest names were breached within months – against a backdrop of nearly 2,000 weekly cyberattacks on organizations globally.
Medtech Insight - April 27, 2026

Sephora Will Safeguard Against Anti-Aging Tween Marketing In Agreement With Connecticut
Connecticut Attorney General William Tong announces he has reached an agreement with retailer Sephora to improve warnings and disclaimers regarding anti-aging products and consumers under the age of 13.
HBW Insight - April 27, 2026

Finance Watch: Sage Executives Return With A New Neurology Start-Up
Private Company Edition: Tortugas Neuroscience emerged with $106m and in-licensed clinical drug candidates, with former Sage CEO Jeff Jonas and CSO Al Robichaud at the helm. Also, Ray Therapeutics raised a $125m series A round and Flagship launched Serif with $50m.
Scrip - April 27, 2026

Premium Supplements Grow But Nutrition Sales Down For Nestlé
Infant formula recall hits sales at Nestlé's Nutrition business, which now houses the firm's dietary supplement lines following an organizational shake-up.
HBW Insight - April 27, 2026

Outgoing Santhera CEO Reflects On Firm’s Remarkable Recovery
Having joined in 2019, faced with a failed lead asset and financial dire straits, Dario Eklund is leaving the Swiss firm in rude health as its Duchenne drug, Agamree, continues to expand.
Scrip - April 27, 2026

Debt To Scale: Shanghvi’s Bold Organon Deal Signals A New Sun Is Rising
Sun’s acquisition of Organon positions it for striking global scale including in markets like China, diversified growth across women’s health, biosimilars and innovative drugs, setting it up for long-term value creation.
Scrip - April 27, 2026

Hikma Abandons 503B Compounding And Strikes Fresh Inhalers Deal
Recently-reinstalled Hikma CEO Said Darwazah is wasting no time in taking action to turn the business around and restore focus, bringing to an end the company’s 503B compounding venture in the US at the same time as striking a fresh device technology to support its planned generic Ellipta inhalers.
Generics Bulletin - April 27, 2026

Eli Lilly Goes From Backer To Buyer With Ajax Deal
Ajax is Lilly's sixth acquisition of 2026 and its second blood-cancer deal in a week.
Scrip - April 27, 2026

Editing Heart Disease Out Of Our DNA
Gene editing medicines for cardiovascular risk are fast becoming a reality, with early data that dwarfs the impact of statins.
In Vivo - April 27, 2026

Formycon Sets Out Growth Strategy After Missing FY2025 Financial Guidance
German biosimilars developer Formycon presented a four-pillar strategy to drive geographic expansion, portfolio growth, operational excellence, and cost efficiency, as it targets positive €60m-€70m in revenue for 2026.
Generics Bulletin - April 27, 2026

Sun Speeds Into Biosimilars With $11.75bn Organon Platform
Sun Pharma will acquire Organon in an $11.75bn deal, gaining an immediate global biosimilars platform, major China and Europe presence, while entering the world’s top 25 drugmakers after nearly doubling revenues.
Generics Bulletin - April 27, 2026

Hard-Hit UK Biotech Lifted By M&A And Financing In Q1
Many UK biotechs were starved of new funds in 2025, but the first quarter of this year saw a rise in overall dealmaking, plus two company buyouts by big pharma.
Scrip - April 27, 2026

Leaders Are Paying For The Wrong Skills, Report Finds
A recent Wharton/Accenture report shows biopharma workers are overselling the wrong skills, employers are rewarding the wrong ones and AI is accelerating the gap.
In Vivo - April 27, 2026

QL Biopharm Unveils Oral Once-Weekly GLP-1 Peptide
Beijing-based QL Biopharm plans to progress the oral GLP-1 peptide ZT006 into a Phase II study to evaluate its once-weekly dosing potential in weight management in the fourth quarter.
Scrip - April 27, 2026

Sun Makes Bold Bet With $11.75bn Organon Deal
Sun snaps up Organon in a deal that is set to transform India’s top-ranked drug maker’s standing globally, giving it global scale and a commanding position in areas like women’s health, established brands and biosimilars.
Scrip - April 27, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO.
Scrip - April 27, 2026